Abstract: PhV (pharmacovigilance) knowledge has the outcome of being inadequate in particular due to the lack of instruction. Pediatricians have to face the realization that over-the-counter medicines increments the peril of ADRs (adverse drug reactions) has become a public health concern. The purpose of this article is to disseminate knowledge of the PhV and to highlight the cultural and organizational difficulties for its implementation. The objectives of promoting the organization of specific training courses and research projects aimed at: (1) to foster the culture of iatrogenic disease in pediatrics; (2) to improve the appropriateness of prescribing drugs in children; (3) to encourage spontaneous reporting of ADRs in children; (4) to involve Pediatricians in PASS (post-authorization safety studies) according to GCP, GVP and ENCEPP Code of Conduct. An up to date proposal of PhV, a procedure of preparation improves the productivity of creating novel informative reports which can be utilized for a benefit/risk scrutiny making strides in medicine prescription. In this context, FP-MCRN (family paediatricians-medicines for children research network) established with the aim of developing competence, infrastructure and education for paediatric clinical trials, plays a crucial role in paediatric PhV, through an improvement of PhV training, a correct research methodology and very strong relationship with the families. The initial necessity is cultural, implementing culture of iatrogenic illnesses and a watchful evaluation of the importance of PASS by FPs (family pediatricians). Participation in clinical trials that generates a precise database administered by FPs together with follow-up outcomes becomes relevant and vital for a scrupulous and accurate assessment of ADRs. PASS can foresee on one hand training and information regarding the proper use of drugs in children and possible iatrogenic pathologies caused by their improper use, the other to constitute a territorial survey in the prescriptive appropriateness and safety of pediatric drugs aimed at evaluating the risk-benefit balance on usage.
Introduction


The risk of ADRs (adverse drug reactions) in children has become a public health concern. In paediatric populations the problem is enhanced by the fact that ADRs are rarely represented in RCCTs (randomized controlled clinical trials). The differences such as pharmacokinetics, pharmacodynamics, epidemiology and co-medication between children and adults in general as well as between children of different age groups, the adverse event and ADR profiles may be different in children and adults. In addition most genetic and rare disease has a childhood onset which adds to the diversity of this population from the adult one [1] [2] [3] [4] .
Paediatricians should be aware that the use of off
Corresponding author: Ettore Napoleone, Pediatrician, President of FP-MCRN, research fields: pediatric drugs. label drugs increases the risk of adverse reactions and they should also try to pay much more attention when they administer drug therapies to their patient [1] [2] [3] [4] [5] [6] [7] [8] . To address the issue of off-label and unlicensed prescribing in children, European regulations were issued with the scope of obliging pharmaceutical companies willing to register new compounds, or indications and formulations, for paediatric use, to submit "paediatric investigation plans" from January 2007 [9] .
In Italy regulatory authorities have increased efforts to enhance awareness of health professionals about the importance of their reporting of ADRs as a significant contribution towards the process of paediatric pharmacovigilance. PASS (post-authorization safety studies), which have been regarded as a strong characteristic to be directed towards the recovery of all events that occur during monitoring, give much more reliable estimates of the risk of ADRs than those resulting from spontaneous reports [10] [11] [12] [13] [14] [15] [16] [17] . The purpose of this article is to disseminate knowledge of the PhV and to highlight the cultural and organizational difficulties for its implementation. The objectives are of promoting the organization of specific training courses and research projects aimed at: (1) to foster the culture of iatrogenic disease in pediatrics; (2) to improve the appropriateness of prescribing drugs in children; (3) to encourage spontaneous reporting of ADRs in children; (4) to involve Pediatricians in PASS (post-authorization safety studies) according to GCP, GVP and ENCEPP Code of Conduct.
The FP-MCRN (Family Paediatricians-Medicines for Children Research Network)
In this contest relevant proactive roles are being played by the FP-MCRN (family paediatricians-medicines for children research network) to develop new methodological approaches and optimise use of available resources, to enable the system to recognise issues of efficacy and safety reducing the health risks for such fragile populations for children as early as possible [1] [2] [3] [4] [5] [6] .
The FP-MCRN, ENCePP and Enpr-EMA member, established with the aim of developing competence, infrastructure, networking and education for paediatric clinical trials, plays a crucial role in paediatric PhV, through an improvement of PhV training, a correct research methodology and very strong relationship with the families. Through specific training (training and educational courses) FP-researchers acquire in fact a correct research methodology according to GCP and GVP (module VIII of the good pharmacovigilance practices on post-authorization safety studies) standards, to the ethical Consideration and to the code of conduct of ENCePP for the conduct of clinical studies on children. FPs (family pediatricians) have a close and elective involvement with children and their families establishing a very strong and close "pediatrician-parents" and "pediatrician-child" relationship. For this reason it becomes easier for the capacity to assess and involve outpatients in clinical trials and the possibility to give more accurate information on the correct use of pediatric drugs [1] [2] [3] [4] [5] [6] .
The "ENCePP Study Seal"
To recognize and study following the ENCePP principles of methodological standards, transparency and independence, the "ENCePP study seal" has been introduced. Studies have to be conducted in accordance with the following principles that may qualify for the "ENCePP study seal": (1) the highest possible level of transparency regarding the use of methodological standards in the study protocol; (2) the contractual arrangements between investigators and the study funder clearly define the research assignment and address critical areas of interaction, remuneration, protocol agreement, analysis of results and publication of results.
The study is registered in the EU PAS Register (ENCePP E-Register of studies) prior to its start, thereby making publicly available information on the research process; the study results (synopsis or manuscript) are published in the EU PAS Register in line with agreed timelines.
In February 15, 2016 a FP-MCRN REDS (respiratory drugs survey) study: active surveillance of respiratory drugs, especially IS (inhaled steroids) in children (AIFA PhV CALL 2010-2011) had awarded with the ENCePP study seal according to principles of methodological standards, transparency and independence [18] .
On 383 pediatric studies in the EU PAS Register only 26 (6.7%) had awarded with the ENCePP study seal. The REDS Study was one of these 26 pediatric studies. This shows that the FP-MCRN has acquired the skills and the experience to build high quality clinical studies, with methodology and scientific rigor.
REDS Study was a PASS conducted in the territory led by family paediatricians that can on the one hand PASS (Post Authorization Safety Studies) 316 predict the FPs training courses and information on families regarding the use of respiratory medication, especially inhaled steroids and any iatrogenic condition caused by their improper use, on the other hand may constitute an active territorial survey on prescriptive appropriateness and safety of these drugs in children aimed at evaluating the risk-benefit balance on usage. This study will enable a wide spread to the FPs GL (guidelines) reference and implement skills (FPs training) for a correct diagnosis, to a viable therapy and closely follow up of pathologies that require the use of these drugs in all children from 0 to 14 years regarding their clinical seriousness. Finally, the study will encourage closer synergy between FPs and families through better and more accurate information given to families on the use of respiratory drugs and in particular of IS will lead to a reduction of the "do it yourself" and self-prescription for illnesses that do not include their use in GL and will certainly lead to a reduction on working days lost by parents and of any hospitalizations (reducing inappropriate admissions) [18] .
Aim
The purpose of this article is to disseminate knowledge of the pharmacovigilance and to highlight the cultural and organizational difficulties for its implementation to create, through the magazine, a debate on the issues that may arise.
Paediatricians should be aware that the use of off label drugs increases the risk of ADRs and they should also try to pay much more attention when they administer drug therapies to their patients. The potential risk of ADRs in children has become a public health concern and regulatory agencies in Europe have acknowledged the need for urgent research efforts in this area. In particular the spontaneous reporting of suspected ADRs is an important means to promote reasonable warning signals. Epidemiological post-marketing studies, which have as a strong characteristic to be directed towards the recovery of all events that occur during monitoring, give much more reliable estimates of the risk of ADRs than those resulting from spontaneous reports. In this context, FP-MCRN (family paediatricians-medicines for children research network) established with the aim of developing competence, infrastructure and education for paediatric clinical trials, plays a crucial role through an improvement of pharmacovigilance academic training, a correct research methodology and very strong relationship with the families
Materials and Methods
In 2013, we performed a survey to evaluate FPs knowledge, feeling and compliance in ADR reporting. A total of 552 FPs evenly distributed throughout the Italian territory provided a feedback to the survey. PhV (knowledge of pharmacovigilance) resulted to be poor, mainly due to the absence of adequate training in academy; despite this, the majority of FPs declared to be interested to PhV and was aware of its positive impact on their clinical practice. Most of FPs considered the academic preparation in PhV "insufficient" (76.5%) and only 1% of the responders defined their preparation as "exhaustive". However, 92% of FPs had the perception that PhV can improve their patients care and 78% would be willing to participate in specific training, if made available. This study provided the first Italian survey on paediatric PhV. It highlights that FPs are aware of PhV importance in their clinical practice while recognizing an insufficient education on it. Considering these observations, we believe that an improvement of PhV academic training, continuous training and information at the territorial level, possibly coordinated at the national and transnational levels may generate a better compliance and thus optimization of ADRs reporting [19] .
Spontaneous Reporting
In Italy, the activity of spontaneous reporting in children is very low: in recent years, paediatric data-reporting has stood at around 1 to 1.6 percent,
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317 compared with 8% of total reporting. Reasons may be different: (1) a non spread of a iatrogenic disease culture over the years' existence; (2) people don't understood the real benefits that the spontaneous reporting system can create for the community in terms of reducing the risks of patients and saving resources [1, 2, 19 ] . Family Pediatricians case reports mainly involve vaccines followed by frequency reports of pharmaceuticals used by children: antibiotics, antipyretics, inhaled corticosteroids, specific products for colds and some drugs belonging to the class of drugs on the gastrointestinal tract and metabolism. Most of the ADRs, observed in pediatric prospective studies, mainly effect the skin (rash, urticaria) and the gastrointestinal system (diarrhea, nausea and vomiting), but we can also observe systemic reactions and reactions connected to the central nervous system [1] [2] [3] [4] [5] [6] [7] .
Very often a major cause of ADRs is determined by the behavior of families, when facing adverse reactions due to a non-rational use of drugs. A high percentage of the accesses to the emergency room for adverse reactions have been registered, after an ingestion of an overdose of medication. The main causes of overdoses are: accidental ingestion of the drug for the lack of adult control, defective or inadequate packaging (for example, the lack of safety lock systems), and the error in the preparation/dilution of a more concentrated drug [1] [2] [3] .
We developed a pilot PhV project named "MEAP (monitoring of the adverse effects in paediatric population)", a design to enhance high quality spontaneous reporting of ADRs in children by both hospital and family paediatricians [2] .
The Italian pharmacological society and family paediatricians decided to act in concert and have generated a "recommendations for quality pediatric pharmacovigilance" guideline, which is currently being distributed to all family paediatricians [2] .
The MEAP project demonstrates that an approach of pharmacoviglinace accompanied by continuous training, sharing of results and easy to fill reporting forms, enhances the effectiveness of generating new informative data which can be exploited for benefit/risk analysis, improving drug prescriptions and ameliorating the current regulation, thus ultimately impacting on paediatric patient safety. Nevertheless much more efforts is needed to guarantee that children will receive the correct medications, appropriate to their clinical conditions [2] .
PASS (Post-Authorization Safety Studies)
When the drug is used in clinical practice in large unselected populations, PAS Studies, according to GCP, GVP and ENCePP code of conduct, are useful as they find their major confirmation in recalling all the events that occur during monitoring, with estimates of incidence of ADRs that cannot be obtained by spontaneous reports. In these studies a significant role can be played by the FP with the participation to active pharmacovigilance projects [1] [2] [3] [4] [5] [6] .
AIFA (The Italian medicines agency) approved, for the first time ever, a project conceived, structured and implemented by the family pediatricians and presented by the Molise region, within the program of active pharmacovigilance funded through the regional funds available for the years 2008 and 2009 [20, 21] .
"From the data OSMED of prescription of pharmaceuticals in which a widespread of antibiotics were calculated, stratified by age, once again there emerges an "over-prescription" of these drugs, especially in the age group between 0 and 2 years. An increase in ADRs related to them is noted. It still seems obvious that inefficient use of these drugs as instructed are not always based on scientific evidence raising the problem of antibiotics-strength and quality of the therapy. Hence the need for a research project, Phase IV, is managed and coordinated in full for the first time with the family pediatrician, that can foresee on one hand training and information regarding the proper use of antibiotics in children and possible iatrogenic pathologies caused by their improper use, the other to 318 constitute a appropriaten aimed at eva The study w data OSME track the dia and of a c various pedi [21] [22] [23] .
The study consisted o (retrospectiv of antibiotic the type of second phas the FPs and and proper u prescribing. It then proceeded to give relief to these aspects of inappropriateness prescriptive disseminating the main aspects of national and international guidelines for paediatricians. In particular, it was forwarded, as shown in the international guidelines (NICE 2008 (NICE -2015 , in the case of a child with a sore throat, that though there are other signs of infection concomitant respiratory tract (nasal discharge, cough) it is certainly a viral disease [20] [21] [22] [23] .
The event has paid particular attention to the importance of promoting research and pharmacological trial culture, by building an even higher skill aimed especially at protecting the most vulnerable one such as the pediatric population, and its attention to the culture of iatrogenic disease for a careful analysis of the risk/benefit ratio of medication for use in children. Also pediatrician colleagues were stimulated to major reporting of adverse reactions in children.
The aims of the project were illustrated and announced that first the data of the pediatric antibiotic prescriptions promot awareness on appropriateness of prescription through the communication of the above mentioned national and international guidelines.
Finally it highlights the information/training work done by family pediatricians with the families of their patients to stress the concept of the proper use of medicines in children, and in particular of antibiotics in the most vulnerable age group, avoiding the "do it yourself" by families, which expose children to the risk of adverse symptoms.
Overall, the importance of proper training is clear for paediatrician's appropriateness of prescribing antibiotics for this vulnerable class of children, correct information for families on knowledge and experience of pediatric medication and the importance of always consulting the pediatrician before "misuse" of medication that do not resolve the clinical solution but rather expose these young patients at risk [21] [22] [23] .
Conclusions
Using a proactive approach means to organize family paediatricians in order to anticipate a possible identification of safety problems, and this reducing community risks.
A future path to follow in pediatrics is undoubtedly towards the synergy and coordination of all components of pediatrics (universities, hospitals, territories) for the organization of research projects and post-marketing programs. The starting point must necessarily be cultural: an implementation of the culture of iatrogenic disease and a careful assessment of the significance of PAS studies by family paediatricians.
From all these considerations, it is clear that we should move in different directions: the knowledge of pharmacovigilance and the involvement of FPs in PASS. There is the need to awaken FP to a culture of iatrogenic disease, to the reporting of ADRs and to the proper use of reporting forms. On the other hand, there is a need for a greater culture of research in pediatric pharmacology leading towards an increasingly pro-active PhV. Moreover, we must be able to seize the opportunities independently from scientific research institutions (AIFA, contract department, FVG regional funds) proposing safety studies on drugs for pediatric trials.
In the study on the antibiotics [21] [22] [23] , after a comparison of prescriptive data of 2013 and the year 2015 after the formation of family pediatricians and the information to families on the proper use of antibiotics and of any adverse events related to their misuse, we had:
(1) A significant decline of 27% of the prevalence of prescriptions has gone from 83% (2013) to 56% (2015);
(2) A reduction in the number of prescriptions equals to 2938 and a reduction of the number of pieces prescribed equals to 2975, maintaining almost unchanged the number of assisted of 0-2 years in the two years under review; The importance of proper training is clear for paediatrician's appropriateness of prescribing antibiotics for this vulnerable class of children, correct information for families on knowledge and experience of pediatric medication and the importance of always consulting the pediatrician before "misuse" of medication that do not resolve the clinical solution but rather expose these young patients at risk.
A significant aspect emerging from the Italian experience is also the importance of the synergy and coordination of paediatricians and pharmacologists for the organization of research projects, and clinical studies in continuous education. Such strategies will lead family paediatricians to regain possession of the research aspect of the profession through the fundamentals of science and the publishing of work about primary care. The organization of specific training courses and research projects should meet the following objectives: (1) promote the culture of iatrogenic disease in pediatrics; (2) improve the appropriateness of prescribing drugs in children; (3) encourage spontaneous reporting of ADRs in children; (4) involve FP in PASS according to GCP, GVP and ENCEPP code of conduct.
Of course, all these supported by capacity building of FP-MCRN is central to epidemiological studies-observational and DBPC-RCT studies on medicines for children. The creation of a specific database managed and coordinated by the FP with follow-up results becomes strategic and very important for a careful and correct evaluation of ADRs. Last but not least, what must also to be mentioned is the fact that with the FP there would be fewer drop-outs in PAS studies if there is a taking charge of children and established close relationship with families.
The main target of family paediatricians should be to regain possession of the research aspect of the profession through the fundamentals of science and the production and publishing of paper work about primary care in order to guarantee greater knowledge and better decision-making. The FP-MCRN must be aware and ready for specific training so that it can answer with authority for independent research. Quality and ethicality of research are becoming important end-points of territorial paediatrics, opportunities and challenges of family paediatricians during their education and during the sponsoring of health and prevention in the paediatric age groups.
